title: Emerging therapies for treatment of multiple sclerosis.
abstract: In the last decade, a new armamentarium of immune-based therapies have been developed and tested in patients with multiple sclerosis. Some of these therapies are showing a high level of efficacy, with an acceptable adverse effect profile. Because present therapies have significant limitations in slowing disease progression, require injections, are sometimes associated with significant side effects of immunosuppression, and do little to reverse disability, identifying more effective treatments is an important goal for clinical research in multiple sclerosis. However, in order to improve our current approach to disease-modifying therapies, it is imperative to promote the development of individualized therapy strategies.
authors.affiliation: Rocky Mountain Multiple Sclerosis Center, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado, USA.
authors.forename: John R
authors.initials: JR
authors.lastname: Corboy
authors.forename: Augusto A
authors.initials: AA
authors.lastname: Miravalle
references.citation: Ann Neurol. 2009 Mar;65(3):304-15
references.pmid: 19334062
references.citation: Expert Opin Investig Drugs. 2009 Aug;18(8):1169-81
references.pmid: 19604118
references.citation: Proc Assoc Am Physicians. 1999 Jan-Feb;111(1):35-44
references.pmid: 9893155
references.citation: Neurology. 2008 Sep 16;71(12):917-24
references.pmid: 18794494
references.citation: Eur J Neurol. 2006 Jun;13(6):604-10
references.pmid: 16796584
references.citation: Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1716-20
references.pmid: 8643695
references.citation: J Immunol. 2009 May 15;182(10):5994-6002
references.pmid: 19414750
references.citation: J Leukoc Biol. 2004 Nov;76(5):950-60
references.pmid: 15328336
references.citation: Nat Neurosci. 2005 Jun;8(6):745-51
references.pmid: 15895088
references.citation: Nat Neurosci. 2004 Jul;7(7):736-44
references.pmid: 15184901
references.citation: J Clin Invest. 1985 Feb;75(2):377-83
references.pmid: 2579098
references.citation: J Neuroimmunol. 2005 Sep;166(1-2):132-43
references.pmid: 15993952
references.citation: Nature. 2003 Apr 17;422(6933):688-94
references.pmid: 12700753
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8705-8
references.pmid: 15161974
references.citation: Arch Neurol. 2009 Apr;66(4):483-9
references.pmid: 19364933
references.citation: N Engl J Med. 2008 Oct 23;359(17):1786-801
references.pmid: 18946064
references.citation: N Engl J Med. 2008 Feb 14;358(7):676-88
references.pmid: 18272891
references.citation: Lancet. 2008 Jun 21;371(9630):2085-92
references.pmid: 18572078
references.citation: J Neurosci. 2007 Jan 3;27(1):220-5
references.pmid: 17202489
references.citation: Ann Neurol. 2005 Nov;58(5):706-19
references.pmid: 16173073
references.citation: J Immunol. 2004 Dec 1;173(11):6981-92
references.pmid: 15557195
references.citation: Neurology. 2008 Oct 14;71(16):1261-7
references.pmid: 18852441
references.citation: Eur J Immunol. 1996 Sep;26(9):2067-74
references.pmid: 8814248
references.citation: Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6
references.pmid: 16585503
references.citation: Br J Pharmacol. 2009 Nov;158(5):1173-82
references.pmid: 19814729
references.citation: Neuropathol Appl Neurobiol. 2007 Feb;33(1):99-107
references.pmid: 17239012
references.citation: Neurology. 2000 Mar 14;54(5):1145-55
references.pmid: 10720289
references.citation: Ann Neurol. 2009 Oct;66(4):460-71
references.pmid: 19847908